A Study of IDP-001 in Advanced or Metastatic Solid Tumors

Study Number

4945626

Phase

I/II

Age Group

Adult

Principal Investigator

Prantesh Jain

Purpose

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).

Check your eligibility for this trial

Check now

Full Title

A Phase 1/2 Open-Label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors

ClinicalTrials.Gov ID

NCT07602842

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.